VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 125 filers reported holding VERVE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,959,525 | -28.6% | 5,200,567 | +1.0% | 0.53% | -17.4% |
| Q2 2023 | $96,578,455 | +49.4% | 5,150,851 | +14.9% | 0.64% | +43.9% |
| Q1 2023 | $64,631,752 | -23.5% | 4,482,091 | +2.7% | 0.44% | -39.3% |
| Q4 2022 | $84,478,811 | -27.5% | 4,365,830 | +28.6% | 0.73% | -10.0% |
| Q3 2022 | $116,579,000 | +278.0% | 3,393,859 | +66.8% | 0.81% | +346.7% |
| Q2 2022 | $30,837,000 | -19.9% | 2,034,124 | +20.6% | 0.18% | +13.0% |
| Q1 2022 | $38,496,000 | -25.4% | 1,686,945 | +20.5% | 0.16% | +3.2% |
| Q4 2021 | $51,601,000 | -13.4% | 1,399,545 | +10.4% | 0.16% | +9.1% |
| Q3 2021 | $59,582,000 | +80.3% | 1,267,705 | +131.2% | 0.14% | +134.4% |
| Q2 2021 | $33,040,000 | – | 548,389 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $28,967,026 | 13.98% |
| Alphabet Inc. | 10,549,086 | $152,117,820 | 8.44% |
| MPM BioImpact LLC | 803,501 | $11,586,484 | 3.01% |
| Casdin Capital, LLC | 2,120,571 | $30,578,634 | 2.52% |
| Novo Holdings A/S | 1,200,000 | $17,304,000 | 1.14% |
| Redmile Group, LLC | 1,120,679 | $16,160,191 | 0.70% |
| Avidity Partners Management LP | 1,351,700 | $19,491,514 | 0.65% |
| ARK Investment Management | 4,482,091 | $64,631,752 | 0.44% |
| BVF INC/IL | 650,000 | $9,373,000 | 0.34% |
| Cormorant Asset Management, LP | 350,000 | $5,047 | 0.33% |